BSE · 539730
Fredun Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹213 Cr with net profit ₹11 Cr — a 5.2% net margin, versus 5.1% the period before.
Shareholding
As of 2026-07-31
- Promoter44.57%
- Public51.43%
- FII1.06%
- DII2.94%
9,598 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.46× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #14 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,319 Cr | 84.56 | 22.04 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,933 Cr | 160.96 | 9.52 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,520 Cr | 113.07 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,811 Cr | 100.55 | 19.25 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,279 Cr | 113.33 | 5.37 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,056 Cr | 66.76 | 4.88 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,793 Cr | 50.54 | 4.55 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,719 Cr | 28.05 | 3.88 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹5,952 Cr | 47.1 | 6.38 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,827 Cr | 141.35 | 4.04 | 8.95% | 11.15% |
| Fredun Pharmaceuticals Limited(this company) | ₹1,569 Cr | 48.12 | 5.83 | 11.73% | 5.91% |
AI analysis
AI-generated · google/gemini-2.5-flashFredun Pharmaceuticals Limited is listed with a market capitalization of Rs 1533 Cr. The company reported a revenue of Rs 639.12 Cr and a profit margin of 5.91%. Earnings per share stand at Rs 19.72, with a Price-to-Earnings ratio of 46.99. The dividend yield is 2%.
Positives
- +The company's dividend yield is 2%.
- +Promoter pledge is 0% as of July 31, 2026.
- +Return on Capital Employed (ROCE) is 15.97%.
Negatives
- −The latest reported promoter holding has decreased to 44.57% from previous periods where pledge percentages were higher.
- −The profit margin is relatively low at 5.91%.
- −The debt-to-equity ratio is 0.93, which could be considered high.
- −No quarterly results were disclosed for September 2024.
- −No revenue growth figure was provided in the data.
Financial Performance
The company recorded a revenue of Rs 639.12 Cr for the latest financial year. Annual net profit was Rs 32.62 Cr for March 2026. Quarterly revenue for March 2026 was Rs 213.06 Cr, with a net profit of Rs 10.78 Cr. This follows a net profit of Rs 10.48 Cr in December 2025 on revenue of Rs 160.92 Cr.
Profitability & Returns
Fredun Pharmaceuticals Limited achieved a Return on Equity (ROE) of 11.73% and a Return on Capital Employed (ROCE) of 15.97%. The profit margin for the company was 5.91%. The earnings per share (EPS) for the latest period was Rs 19.72.
Balance Sheet
The company has a book value of Rs 162.78. The debt-to-equity ratio is 0.93, indicating that for every Rupee of equity, the company has Rs 0.93 of debt. There are no reported promoter pledges.
Ownership & Pledges
Public shareholding stands at 51.43%. Total institutional holding is 4.00%.
Regulatory & Surveillance
The company is not currently under any surveillance measure. There were no reported promoter pledges as of the latest shareholding data for July 31, 2026. However, promoter pledge historically was 5.54% in December 2019.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jul 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Fredun Pharmaceuticals Limitedshare price & fundamentals